Analysis of the role of the shedding protease ADAM 17 in vivo (A01)

• Subject Area: Immunology ; Metabolism, Biochemistry and Genetics of Microorganisms
• Term: from 2010 to 2022
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 125440785

ADAM17 is the major shedding protease for substrates such as IL-6R, TNFα and ligands of the EGF receptor (EGF-R). ADAM17 is protective in animal models of atherosclerosis and stroke. In contrast, ADAM17 deficiency prevented kidney fibrosis and intestinal tumorigenesis. In the next funding period, the role of ADAM17 in auto-inflammatory models will be studied to understand how the activation of the ADAM17-EGF-R-IL-6 axis contributes to autoimmune diseases in general and whether blocking ADAM17 can be exploited therapeutically.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 877: Proteolysis as a Regulatory Event in Pathophysiology
• Applicant Institution: Christian-Albrechts-Universität zu Kiel
• Project Heads: Dr. Athena Chalaris, until 7/2016; Professor Dr. Stefan Rose-John